维奈托克与地西他滨治疗儿童难治性T细胞淋巴母细胞淋巴瘤
Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.
作者信息
Baig Muhammad U, Rytting Michael, Roth Michael, Morani Ajaykumar C, Nunez Cesar, Lin Pei, Cuglievan Branko
机构信息
Departments of Pediatrics.
Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
J Pediatr Hematol Oncol. 2021 Oct 1;43(7):e991-e996. doi: 10.1097/MPH.0000000000002050.
BACKGROUND
Overall survival of adolescents with relapsed T-cell lymphoblastic lymphoma (T-LL) remains poor with limited options for salvage therapy. The BCL-2 inhibitor venetoclax combined with hypomethylating agents like decitabine, has shown favorable responses in elderly patients with acute myeloid leukemia.
OBSERVATION
We present the case of a 19-year-old adolescent with stage III relapsed and refractory T-LL who did not respond to 3 lines of salvage therapy. The patient was treated with venetoclax and decitabine and achieved a dramatic response.
CONCLUSION
This case highlights the potential clinical activity of venetoclax and decitabine in relapsed T-LL.
背景
复发的T细胞淋巴母细胞淋巴瘤（T-LL）青少年患者的总生存期仍然很差，挽救治疗选择有限。BCL-2抑制剂维奈托克联合地西他滨等去甲基化药物，已在老年急性髓系白血病患者中显示出良好疗效。
观察
我们报告了一例19岁的III期复发难治性T-LL青少年患者，该患者对3线挽救治疗均无反应。该患者接受维奈托克和地西他滨治疗后取得了显著疗效。
结论
该病例突出了维奈托克和地西他滨在复发T-LL中的潜在临床活性。
Zotero 插件